Women and Alcoholism: An Individual Patient Data (IPD) Meta-Analysis of Outcome Predictors Based on 935 Female Patients in 16 Acamprosate Clinical Trials

Mason, Barbara;Lehert, Philippe
(2006) American Society of Addiction ASAM’s 38th Annual Medical Scientific Conference April 26-29, 2006 — Location: Miami, USA

Files

No attached file found for this publication.

Details

Authors
  • Mason, Barbara
    Author
  • Lehert, Philippeorcid-logoFUCaM
    Author
Abstract
(en) Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A meta-analysis was carried out to compare acamprosate with placebo on women patients on TA and CA. 21 randomized, placebo-controlled trials (RCTs) that fulfilled predetermined selection criteria were identified. Primary outcome measures were percent days of TA (defined as zero drinks during the treatment interval) and CA (defined as <5 standard drinks/day during the treatment interval). TA and CA rates were also significantly higher with patients treated with acamprosate vs. placebo (43.5% vs. 23.2%; RR, 0.64; P<.001) with an NNT=5.8. Acamprosate can provide a significant benefit in women by reducing alcohol consumption during relapse.
Affiliations
  • Louvain School of Management

Citations

  • APA
  • Chicago
  • FWB

Mason, B., & Lehert, P. (2006). Women and Alcoholism: An Individual Patient Data (IPD) Meta-Analysis of Outcome Predictors Based on 935 Female Patients in 16 Acamprosate Clinical Trials. American Society of Addiction ASAM’s 38th Annual Medical Scientific Conference April 26-29, 2006, Miami, USA. https://hdl.handle.net/2078.5/128941